MedPath

PR-104

Generic Name
PR-104
Drug Type
Small Molecule
Chemical Formula
C14H20BrN4O12PS
CAS Number
851627-62-8
Unique Ingredient Identifier
V16D2ZT7DT

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors
Phase 1
Completed
Posted: 2011/05/23
Sponsor:
Proacta, Incorporate...
ID:NCT01358227
PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia
Phase 1
Posted: 2009/12/23
Sponsor:
Proacta, Incorporate...
ID:NCT01037556
Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Terminated
Posted: 2009/03/16
Sponsor:
Proacta, Incorporate...
ID:NCT00862134
PR104 and G-CSF in Treating Patients With Solid Tumors
Phase 1
Completed
Posted: 2008/02/15
Sponsor:
Proacta, Incorporate...
ID:NCT00616213
PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
Phase 2
Terminated
Posted: 2007/10/16
Sponsor:
Proacta, Incorporate...
ID:NCT00544674

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy